GlassScriptPhysician profile
Natalia E Pajak
NPI 1487096855
$478.05
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $105.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.18 | 2021-2022 | |
| Blue Earth Diagnostics | $51.24 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.86 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $47.64 | 2021 | |
| Dendreon Pharmaceuticals LLC | $46.59 | 2021 | |
| Merck Sharp & Dohme LLC | $39.97 | 2021-2022 | |
| Pfizer INC. | $27.63 | 2021-2022 | |
| 180 Medical, INC. | $27.51 | 2021 | |
| Abbvie INC. | $21.06 | 2021 | |
| Urovant Sciences INC | $20.66 | 2021 | |
| Boston Scientific Corporation | $20.42 | 2021 | |
| Clarus Therapeutics INC. | $19.21 | 2021 | |
| Antares Pharma, INC. | $17.83 | 2021 | |
| Teleflex LLC | $15.60 | 2021 | |
| Procept Biorobotics Corporation | $14.65 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Pajak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.